With a growing number of protein therapeutics being developed, many of them exhibiting a
short plasma half-life, half-life extension strategies find increasing attention by the biotech …

Background Albumin is the most abundant plasma protein, is highly soluble, very stable and
has an extraordinarily long circulatory half-life as a direct result of its size and interaction …

The neonatal Fc receptor (FcRn) was first found to be responsible for transporting antibodies
of the immunoglobulin G (IgG) class from the mother to the fetus or neonate as well as for …

Antibody technologies are being increasingly applied in the field of toxinology. Fuelled by
the many advances in immunology, synthetic biology, and antibody research, different …

Albumin is the most abundant protein in blood and acts as a molecular taxi for a plethora of
small insoluble substances such as nutrients, hormones, metals and toxins. In addition, it …

A major challenge for the therapeutic use of many peptides and proteins is their short
circulatory half-life. Albumin has an extended serum half-life of 3 weeks because of its size …

Albumin is the most abundant protein in blood where it has a pivotal role as a transporter of
fatty acids and drugs. Like IgG, albumin has long serum half-life, protected from degradation …

Both conventional and innovative biomedical approaches require cost-effective protein
drugs with high therapeutic potency, improved bioavailability, biocompatibility, stability and …

Albumin is the most abundant plasma protein involved in the transport of many compounds,
such as fatty acids, bilirubin, and heme. The endothelial cellular neonatal Fc receptor (FcRn) …

Proteins are synthesized in heterologous systems because of the impossibility to obtain
satisfactory yields from natural sources. The production of soluble and functional …